Phenylketonuria Market
Phenylketonuria Market: information by Product Type (Drugs, Dietary Supplement) Rout of Administration (Oral Route), Distribution Channel (Hospital Pharmacies, Drug Stores)—Forecast Till 2026
Market Overview
The Phenylketonuria market accounted for around USD 858.2 million in 2018 and is expected to grow at a CAGR of 6.3% during the forecast period, 2019–2026.
Phenylketonuria is an inborn genetic disorder, in which decreased metabolism of the amino acid phenylalanine. It is a rare genetic disorder that increases the level of phenylalanine in the blood and causes problems throughout the body. Phenylketonuria is major causes of seizures, intellectual disability, mental disorder, and behavioral problems.high prevalence of phenylketonuria across the globe is driving the growth of market. For instance, according to the Boston Children's Hospital, around one in 15,000 babies are born with PKU in the United States every year.
Growing number of pipeline of product for treatment of phenylketonuria is boosting the growth of market. For instance, CNSA-001 developed by Censa pharmaceuticals, Inc. is under Phase 2.
Market Snapshot
Segmental Analysis
Phenylketonuria market is segmented by product type, rout of administration and distribution channel.
On the basis of product type, the market is segmented into drugs and dietary supplement.drug is further segmented into kuvan and biopten.
Based on rout of administration, the market is segmented into oral route and parenteral route.oral route is further segmented into tablets & capsules, syrups and powder.parenteral route is further segmented into intravenous and subcutaneous. oral route is expected to hold major market share owing to dose flexibility and acceptable size and volume.
On the distribution channel, the market is segmented into hospital pharmacies, drug stores, online pharmacies and pediatric clinics. hospital pharmacies is expected to hold major market share over the forecast period.
Regional Analysis
Geographically, the phenylketonuria market is segmented into four North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is dominating the market and expected to grow over forecast period.According to the CanPKU in U.S. Phenylketonuria test is recommended as the first condition widely tested for through newborn screening. Increasing research and development and development for development of advanced treatment is propelling the growth of market. For instance, May 2018, U.S. Food and Drug Administration approved Palynziq (pegvaliase-pqpz) for treatment of phenylketonuria.
Europe accounted for second largest share for phenylketonuria market. Increasing number incidences of phenylketonuria in several European countries is boosting the growth of market. For instance, according to the NHS England, during 2015–2016, it was estimated approximately, 1 per 10,000/14,000 diagnosed with phenylketonuria. Furthermore, Different nonprofit organization work for management of phenylketonuria is fueling the growth of market. For instance, - European Society for Phenylketonuria and Allied Disorders, has been published in the Orphanet Journal of Rare Diseases for increasing awareness of phenylketonuria.
Top Key Players of Phenylketonuria Market
Some of the key players in the phenylketonuria market include
- ambrooke Therapeutics
- Daiichi Sankyo Company Limited
- American Gene Technologies International INC.
- Danone Nutricia
- Dimension Therapeutics INC.
- Synthetic Biologics INC.
- SOM Innovation Biotech SL
- Codexis INC.
- BioMarin Pharmaceutical INC.
- Erytech Pharma SA
Report Scope
| Report Metric | Details |
|---|---|
| CAGR | 6.3% |
| Forecast Period | 2023-2031 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Segments Covered |
|
| Geographies Covered |
|
Recent Developments
What will be the Future Developments in Phenylketonuria Market?
- Historical inferences, findings & analysis of the market from 2016 to 2018
- Projections and performance forecast analysis for the future from 2019 to 2026
- Production and consumption point of view (POV) analysis
- Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
- Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects
Phenylketonuria Market Segmentation
By Product Type
- Drugs
- Kuvan
- Biopten
- Dietary Supplement
By Rout of Administration
- Oral Route
- Tablets and Capsules
- Syrups
- Powder
- Parenteral Route
- Intravenous
- Subcutaneous
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Pediatric Clinics
Regions Covered
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
USD 995
Purchase Benefits
- Eligible for a free updated report next year
- Completely customizable scope
- 30% discount on your next purchase
- Dedicated account manager
- Query resolution within 24 hours
- Permission to print the report
Report Benefits
- Develop business strategies by understanding the trends shaping and driving the Market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track sales in the global and country-specific Market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
